Recent Advances and Challenges in Liquid Biopsy-Based Cancer Research
Abacus dx is happy to be able to present to you a Streck-sponsored on-demand webinar presented by Prof. Dr. med. Stefan Holdenrieder.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).